ArticleVirology journal2024
A comprehensive seroepidemiology of dengue and chikungunya arboviruses in Iran, 2020-2023.
Article in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Investigation of chikungunya arbovirus in cities of Bushehr province: An ELISA-based cross-sectional study.Virus research · 2026Article
- Distribution of Aedes aegypti and Aedes albopictus, and the current situation of dengue fever and chikungunya in Iran and neighboring countries: a review study.PLoS neglected tropical diseases · 2026Review
- A national report on 2024 dengue fever outbreak in Iran: has the game changed?BMC infectious diseases · 2025Article
- A qualitative study to identify the determinants and strategies for the prevention of dengue fever in Iran.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimDengue virus (DENV) and Chikungunya virus (CHIKV) are the most common arthropod-borne viruses (Arboviruses) globally. So far, no autochthonous cases of DENV and CHIKV infections have been reported in Iran. Nevertheless, due to the recent identification of Aedes aegypti in the south and Aedes albopictus in the north of Iran, the country is at a serious risk of local outbreaks of these infections.
methodsBetween 2020 and 2023, a comprehensive cross-sectional study was conducted to explore the anti-DENV and CHIKV IgG antibodies in the general populations of both southern and northern regions of Iran using ELISA.
resultsA total of 11,192 participants were included, of whom 2.3% (256 individuals) and 0.1% (11 cases) were DENV seropositive and CHIK seropositive, respectively. Across the eight examined provinces, Sistan and Baluchestan province displayed the highest prevalence of dengue seropositive cases (6.80%) (P < 0.001). Samples collected in 2022 demonstrated a notably higher seropositive rate of 5.5% (P < 0.001). Interestingly, all 11 CHIKV seropositive cases were from Sistan and Baluchestan province.
conclusionThe seroprevalence of DENV was notably higher in southern regions, particularly in Sistan and Baluchestan province and CHIKV seropositive cases were exclusively found in Sistan and Baluchestan province. This study furnishes crucial insights into the seroepidemiology of DENV and CHIKV in Iran, which in conjunction with the presence of Ae. aegypti in the south and Ae. albopictus in the north of Iran, emphasizes the requirement of improving integrated surveillance and control systems in the whole of the country, especially in the south of Iran.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.